AQR Capital Management
RIGL icon

AQR Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

AQR Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.88M Buy
124,801
+33,793
+37% +$1.04M ﹤0.01% 2019
2026
Q1 		$2.46M Sell
91,008
-18,728
-17% -$629K ﹤0.01% 2217
2025
Q4 		$4.7M Buy
109,736
+53,135
+94% +$2M ﹤0.01% 1593
2025
Q3 		$1.6M Buy
56,601
+46,563
+464% +$1.39M ﹤0.01% 2124
2025
Q2 		$188K Sell
10,038
-588
-6% -$11.1K ﹤0.01% 3063
2025
Q1 		$191K Buy
+10,626
New +$216K ﹤0.01% 2901
2022
Q2 		– Sell
-3,111
Closed -$93K – 2280
2022
Q1 		$93K Sell
3,111
-1,488
-32% -$40.3K ﹤0.01% 2143
2021
Q4 		$122K Hold
4,599
– – ﹤0.01% 2133
2021
Q3 		$167K Hold
4,599
– – ﹤0.01% 2164
2021
Q2 		$200K Hold
4,599
– – ﹤0.01% 2143
2021
Q1 		$157K Sell
4,599
-345
-7% -$13.7K ﹤0.01% 2136
2020
Q4 		$173K Buy
4,944
+2,520
+104% +$73K ﹤0.01% 2107
2020
Q3 		$58K Buy
+2,424
New +$59.5K ﹤0.01% 2165
2019
Q1 		– Sell
-3,939
Closed -$91K – 2212
2018
Q4 		$91K Sell
3,939
-2,239
-36% -$63.2K ﹤0.01% 2151
2018
Q3 		$198K Buy
6,178
+2,496
+68% +$74.9K ﹤0.01% 2195
2018
Q2 		$104K Buy
+3,682
New +$131K ﹤0.01% 2290
2015
Q2 		– Sell
-2,612
Closed -$93K – 2252
2015
Q1 		$93K Sell
2,612
-17,310
-87% -$475K ﹤0.01% 2083
2014
Q4 		$452K Sell
19,922
-9,208
-32% -$186K ﹤0.01% 2015
2014
Q3 		$565K Sell
29,130
-32,870
-53% -$929K ﹤0.01% 1896
2014
Q2 		$2.25M Sell
62,000
-9,770
-14% -$332K 0.01% 1228
2014
Q1 		$2.79M Buy
71,770
+16,320
+29% +$582K 0.01% 1121
2013
Q4 		$1.58M Buy
55,450
+15,870
+40% +$466K ﹤0.01% 1490
2013
Q3 		$1.42M Sell
39,580
-1,840
-4% -$67.2K 0.01% 1466
2013
Q2 		$1.38M Buy
+41,420
New +$1.88M ﹤0.01% 1410

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management's RIGL Position: Q2 2026 in Review

AQR Capital Management increased its Rigel Pharmaceuticals (RIGL) stake by 37% in Q2 2026, buying an estimated $1.04M and bringing the position to 124,801 shares worth $4.88M. The position accounts for ﹤0.01% of the portfolio, ranked #2019.

AQR Capital Management first reported a position in RIGL in Q2 2013 and has held it in 24 quarters since. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • AQR Capital Management held 124,801 shares of Rigel Pharmaceuticals worth $4.88M as of Q2 2026.
  • AQR Capital Management bought 33,793 Rigel Pharmaceuticals shares in Q2 2026, an estimated $1.04M.
  • Rigel Pharmaceuticals made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #2019 holding.
  • AQR Capital Management first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.